Racing Towards the Development of Diagnostics for a Novel Coronavirus (2019-nCoV)

作者
Yuk Ming Dennis Lo,Rossa W. K. Chiu
出处
期刊:Clinical Chemistry [American Association for Clinical Chemistry]
卷期号:66 (4): 503-504 被引量:26
标识
DOI:10.1093/clinchem/hvaa038
摘要

In December 2019, a mysterious viral illness causing pneumonia broke out in the city of Wuhan, in Hubei Province in China. A proportion of the earlier cases were associated with a seafood market in the city, where exotic animals were also sold for food (1). Since then, this illness has been shown to be caused by a novel coronavirus (nCoV) that is named 2019-nCoV, and the disease named as coronavirus disease 2019 (COVID-19). As of February 26, 2020, the disease has been confirmed in over 80 900 cases, with over 2760 deaths. Geographically, the disease has spread beyond China to close to 40 other countries. The sensitive and specific detection of this virus is an important part of the global healthcare response to this outbreak. In this issue of the journal, Chu et al. (2) reported the development of two one-step real-time reverse transcription polymerase chain reaction assays for detecting 2019-nCoV. The 2 assays target the Orf1b and the N region of the viral genome. Due to the relative paucity of positive control materials when the authors developed these assays, the authors had designed the primers and probes such that they would also cross-react with the Severe Acute Respiratory Syndrome (SARS)-CoV. The authors then use SARS-CoV as one of their positive controls. The authors argued that this cross-reactivity would not cause any diagnostic ambiguity as SARS-CoV was no longer seen clinically following the resolution of the SARS epidemic in 2004. The authors found that the N assay was more sensitive than that targeting the Orf1b. The authors proposed using the former as a screening assay, and the latter as a diagnostic assay. On the basis of the data presented by the authors, one can perhaps argue that this two-tier test arrangement should be considered provisional. Further validation of this approach using a much larger sample cohort would be necessary. When the authors designed their assays, only one 2019-nCoV sequence was publicly available. However, since then, several other 2019-nCoV sequences became available (3,). It will be essential to reassess the specificity of the authors’ primers and probes as the sequence database and biobank for 2019-nCoV grow. It also will be important to compare the performance of the authors’ assays versus those developed by other workers in the field (1). Additionally, it will be necessary to assess the quantitative performance of the authors’ assays in a clinical context, using serial samples. Exploration of the viral kinetics in various sample types and looking for correlations with clinical outcome will be valuable. Viral kinetics studies will be beneficial in identifying treatment modalities that may be effective in inhibiting viral replication. Viral diagnostics is one important part of our armamentarium against COVID-19. Public health measures, such as decisions to place a person and his or her close contacts under medical isolation, surveillance, or quarantine are intimately related to whether a suspected case has been confirmed to be infected with 2019-nCoV. To combat an epidemic, time is of the essence and hence the rapid development of sensitive and specific diagnostic tests is crucial. It is hoped that new therapies and even vaccines might eventually become available for this disease. The emergence of such viral zoonoses is indeed testing modern global healthcare and collaboration to the extreme. All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest: Y.M.D. Lo, Clinical Chemistry, AACC; R.W.K. Chiu, Clinical Chemistry, AACC. None declared. None declared. None declared. None declared. None declared. None declared.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
可爱的函函的应助被Tianna采纳,获得10
刚刚
刚刚
柳贯一发布了新的文献求助10
刚刚
1秒前
1秒前
甜甜寄凡完成签到 ,获得积分10
2秒前
2秒前
3秒前
4秒前
渡花发布了新的文献求助10
6秒前
7秒前
wang关注了科研通微信公众号
7秒前
promise发布了新的文献求助10
7秒前
7秒前
江添盛望完成签到,获得积分10
8秒前
8秒前
福yyy发布了新的文献求助10
8秒前
9秒前
9秒前
鲤鱼芒果完成签到 ,获得积分10
9秒前
9秒前
小河流水完成签到 ,获得积分10
10秒前
慕青的应助被霡霂采纳,获得10
10秒前
10秒前
小豹7087完成签到,获得积分10
11秒前
12秒前
爱吃蛋挞完成签到,获得积分10
12秒前
JohnRyan完成签到,获得积分10
14秒前
14秒前
14秒前
Menand发布了新的文献求助10
15秒前
15秒前
猪猪侠发布了新的文献求助10
15秒前
16秒前
16秒前
wang发布了新的文献求助10
16秒前
16秒前
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186750
求助须知:如何正确求助?哪些是违规求助? 9575059
关于积分的说明 21839377
捐赠科研通 7784384
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559211
邀请新用户注册赠送积分活动 2481653